# BioCryst Pharmaceuticals clinical trials: 54 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 54 trials with BioCryst Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by BioCryst Pharmaceuticals: 54 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/biocryst-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 54
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 54, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 14, 2025 | NCT07228559 | A Study of Avoralstat In Participants With Diabetic Macular Edema | BioCryst Pharmaceuticals | Phase 1 | Terminated | Diabetic Macular Edema (DME) | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228559) |
| August 6, 2024 | NCT06539507 | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 | BioCryst Pharmaceuticals | Phase 1 | Active not recruiting | Netherton Syndrome | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06539507) |
| October 25, 2023 | NCT06100900 | Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) | BioCryst Pharmaceuticals | Phase 1 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06100900) |
| February 23, 2023 | NCT05741346 | Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria | BioCryst Pharmaceuticals | Phase 2 | Terminated | Paroxysmal Nocturnal Hemoglobinuria | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05741346) |
| July 12, 2022 | NCT05453968 | Berotralstat Treatment in Children With Hereditary Angioedema | BioCryst Pharmaceuticals | Phase 3 | Active not recruiting | Hereditary Angioedema, Pediatric | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05453968) |
| December 17, 2021 | NCT05162066 | Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A... | BioCryst Pharmaceuticals | Phase 2 | Terminated | Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05162066) |
| November 11, 2021 | NCT05116787 | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy | BioCryst Pharmaceuticals | Phase 2 | Terminated | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05116787) |
| November 11, 2021 | NCT05116774 | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy | BioCryst Pharmaceuticals | Phase 2 | Terminated | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05116774) |
| June 22, 2021 | NCT04933721 | Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies | BioCryst Pharmaceuticals | Phase 3 | Enrolling by invitation | Hereditary Angioedema, HAE | 139 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04933721) |
| January 11, 2021 | NCT04702568 | A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | BioCryst Pharmaceuticals | Phase 2 | Terminated | Paroxysmal Nocturnal Hemoglobinuria, PNH | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04702568) |
| June 11, 2020 | NCT04428632 | Oral Berotralstat Expanded Access Program | BioCryst Pharmaceuticals | Not applicable | Approved for marketing | Hereditary Angioedema, HAE, Prophylaxis | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04428632) |
| April 1, 2020 | NCT04330534 | First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH | BioCryst Pharmaceuticals | Phase 1/2 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04330534) |
| March 27, 2019 | NCT03891420 | A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 | BioCryst Pharmaceuticals | Phase 1 | Terminated | COVID-19, Yellow Fever | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03891420) |
| March 13, 2019 | NCT03873116 | Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan | BioCryst Pharmaceuticals | Phase 3 | Completed | Hereditary Angioedema, HAE | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03873116) |
| January 11, 2019 | NCT03800173 | A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 | BioCryst Pharmaceuticals | Phase 1 | Completed | Marburg Virus Disease | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03800173) |
| April 3, 2018 | NCT03485911 | Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE | BioCryst Pharmaceuticals | Phase 3 | Completed | Hereditary Angioedema, HAE | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03485911) |
| March 21, 2018 | NCT03472040 | A Long Term Safety Study of BCX7353 in Hereditary Angioedema | BioCryst Pharmaceuticals | Phase 2/3 | Completed | Hereditary Angioedema, HAE, Prophylaxis | 387 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03472040) |
| August 4, 2017 | NCT03240133 | Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema | BioCryst Pharmaceuticals | Phase 2 | Completed | Hereditary Angioedema (HAE) | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03240133) |
| June 29, 2017 | NCT03202784 | A Relative Bioavailability Study of Two Formulations of BCX7353 | BioCryst Pharmaceuticals | Phase 1 | Completed | Hereditary Angioedema | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03202784) |
| May 2, 2017 | NCT03136237 | A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions | BioCryst Pharmaceuticals | Phase 1 | Completed | Hereditary Angioedema | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03136237) |
| August 18, 2016 | NCT02870972 | Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema | BioCryst Pharmaceuticals | Phase 2 | Completed | Hereditary Angioedema (HAE) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02870972) |
| June 30, 2016 | NCT02819102 | An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates | BioCryst Pharmaceuticals | Phase 1 | Completed | Hereditary Angioedema | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02819102) |
| February 2, 2016 | NCT02670720 | Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema | BioCryst Pharmaceuticals | Phase 3 | Terminated | Hereditary Angioedema, HAE | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02670720) |
| December 21, 2015 | NCT02635724 | Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza | BioCryst Pharmaceuticals | Phase 3 | Completed | Influenza | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02635724) |
| May 19, 2015 | NCT02448264 | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese... | BioCryst Pharmaceuticals | Phase 1 | Completed | Hereditary Angioedema | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02448264) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 1/2 | 4 |
| Phase 2 | 20 |
| Phase 2/3 | 2 |
| Phase 3 | 12 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 37 |
| Terminated | 11 |
| Active not recruiting | 2 |
| Withdrawn | 2 |
| Approved for marketing | 1 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Angioedemas, Hereditary | 17 |
| Influenza, Human | 9 |
| Hemoglobinuria, Paroxysmal | 6 |
| Lymphoma | 6 |
| Gout | 4 |
| Hyperuricemia | 4 |
| Leukemia | 4 |
| Lymphoma, T-Cell, Cutaneous | 4 |
| Mycosis Fungoides | 4 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Sezary Syndrome | 3 |
| Arthritis | 2 |
| Joint Diseases | 2 |
| Burkitt Lymphoma | 2 |
| Cough | 2 |
| Pharyngitis | 2 |
| Nasal Obstruction | 2 |
| Headache | 2 |
| COVID-19 | 1 |
| Yellow Fever | 1 |
| Marburg Virus Disease | 1 |
| Renal Insufficiency | 1 |
| Neoplasms | 1 |
| Leukemia, Biphenotypic, Acute | 1 |
| Lymphoma, Large-Cell, Anaplastic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Dentistry schools in the United States](https://specstream.ai/data/businesses/dentistry-schools/united-states)
- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Executive search firms in the United States](https://specstream.ai/data/businesses/executive-search-firms/united-states)
- [Asian fusion restaurants in the United States](https://specstream.ai/data/businesses/asian-fusion-restaurants/united-states)
